MEDADVISOR LIMITED (MDR)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
MDR - MEDADVISOR LIMITED
FNArena Sector :
Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -5.54
Index:
FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -5.54
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$0.295
26 Apr |
-0.010 OPEN $0.30 |
-3.28% HIGH $0.30 |
162,929 LOW $0.29 |
TARGET | |||||
|
OTHER COMPANIES IN THE SAME SECTOR | |||
ACL . AHX . ALC . BMT . CAJ . DOC . EBO . HLS . M7T . MPL . MVF . NHF . PSQ . RHC . SHL . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY22 Actual |
FY23 Actual |
FY24 Forecast |
FY25 Forecast |
---|---|---|---|---|
EPS (cps) | xxx | N/A | - 0.1 | xxx |
DPS (cps) | xxx | N/A | 0.0 | xxx |
EPS Growth | xxx | N/A | N/A | xxx |
DPS Growth | xxx | N/A | N/A | xxx |
PE Ratio | xxx | N/A | N/A | xxx |
Dividend Yield | xxx | N/A | 0.0% | xxx |
Div Pay Ratio(%) | xxx | N/A | N/A | xxx |
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | -2.1 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 98.0 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 11.0 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -1.5 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -11.54 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -27.24 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -21.89 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | -12.97 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | -27.24 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -14.09 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -1.6 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 12 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 13 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 47 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 14 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 2.27 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 0.2 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 0.18 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 85 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 20 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 8 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
MDR STOCK CHART
FNArena News on MDR
1 |
Australian Broker Call *Extra* Edition – Mar 12, 2024Mar 12 2024 - Daily Market Reports |
2 |
FNArena Corporate Results Monitor – 01-03-2024Mar 01 2024 - Australia |
3 |
Australian Broker Call *Extra* Edition – Feb 06, 2024Feb 06 2024 - Daily Market Reports |
4 |
Australian Broker Call *Extra* Edition – Dec 13, 2023Dec 13 2023 - Daily Market Reports |
5 |
Australian Broker Call *Extra* Edition – Dec 06, 2023Dec 06 2023 - Daily Market Reports |
Latest Healthcare services News
1 |
Capitol Health’s Higher Margin OutlookMar 13 2024 - Small Caps |
2 |
Treasure Chest: Ramsay Health CareOct 26 2023 - Treasure Chest |
3 |
Timing Seems Right For Alcidion GroupJun 21 2023 - Small Caps |
4 |
No Enthusiasm To Combine ACL & HealiusMar 21 2023 - Australia |
5 |
Dr Boreham’s Crucible: AlcidionDec 13 2022 - Small Caps |
6 |
No Straight Covid-Relief For Ramsay Health CareNov 15 2022 - Australia |
7 |
Dr Boreham’s Crucible: Mach7 TechnologiesNov 14 2022 - Small Caps |
8 |
Negative Industry Trends Impact Australian Clinical LabsAug 12 2022 - Small Caps |
9 |
Healius Offers Digital Carrot, Base Remains SoftMay 25 2022 - Australia |
10 |
Ramsay Stakes Future on Mental HealthDec 20 2021 - Australia |